Med. praxi. 2014;11(1):22-25

The use of strong opioids in chronic pain treatment

MUDr.Eva Hegmonová
Centrum pro léčbu bolesti a paliativní medicínu, s. r. o., Zlín

The effective management of chronic pain is fundamental goal for all clinicians, who treat the pain. Nociceptive and neuropathic pain

are two basic kinds of pain, which appears separetly or in combination. The three-step analgesic ladder developed by the World Health

Organisation (WHO) outlines these opioids in the management of cancer pain, and these widely accepted and extensively validated

guidelines have also been influential in the application of opioid therapy for treatment of chronic, non-malignant pain.

Potent opioids – such as morfin and the newer-generation agents (fentanyl, buprenorfin, oxycodon, hydromorfon and tapentadol) play

an important role in management of pain in patients with chronic pain. New opioid tapentadol is the first compound of the new pharmacological

class MOR-NRI, that combines μ-opioid-agonist and noradrenalin re-uptake inhibitor activities in one molecule.

Keywords: gabapentinoids drugs, opioids drugs, oxycodon, naloxon, tapentadol

Published: February 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hegmonová E. The use of strong opioids in chronic pain treatment. Med. praxi. 2014;11(1):22-25.
Download citation

References

  1. Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, Nurmko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.Eur J Neurol 2010; 17: 1113-1123. Go to original source... Go to PubMed...
  2. Eissenberg E, Mc Nicol ED, Car DB. Efficacy of mi-opioi agonist in treatment of evoked neuropathic pain: systematic review of randomized controlled trials. Eur J Pain 2006; 10: 667-676. Go to original source... Go to PubMed...
  3. Kršiak M. Dávkování paracetamolu u dospělých s ohledem na hmotnost a kinetiku: simulace na počítači. Bolest 2011; 14(1): 23-28.
  4. Kršiak M. Novinky ve farmakologii opioidů s významem pro praxi. Paliat med lecba bolesti 2010; 3(1): 28-30.
  5. Riviiere PJ. Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol 2004; 141: 1331-1334. Go to original source... Go to PubMed...
  6. Staal C, Dimcevski AM, Anderson SD, et al. A comparative study of oxycodone and morfine in multimodal tissue differented experimental pain model. Pain 2006; 123: 28-36. Go to original source... Go to PubMed...
  7. Rokyta R, Kršiak M, Kozák J. Bolest Tigis, Praha 2012 přepracované doplněné vydání Bolest 2012; 24: 250.
  8. Rowbotham MC, Twilling L, Davies PS, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348(13): 1223-1232. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.